Wei Chen
Wei Chen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Qin Ma
Xinjiang Huashidan Pharmaceutical Research Co., Ltd, Urumqi, China
2 shared publications Bing-Gang Fu
Xinjiang Huashidan Pharmaceutical Research Co., Ltd, Urumqi, China
1 shared publicationGvlzapar Tohniyaz
Xinjiang Huashidan Pharmaceutical Research Co., Ltd, Urumqi, China
1 shared publication- Jie Zhang
School of Chemistry and Chemical Engineering, Key Laboratory for Green Processing of Chemical Engineering of Xinjiang Bingtuan, Shihezi University, Shihezi 832003, PR China
1 shared publication Liang Guo
Shihezi University, Shihezi, Xinjiang, China
1 shared publication- Liang Guo
School of Chemistry and Chemical Engineering, Key Laboratory for Green Processing of Chemical Engineering of Xinjiang Bingtuan, Shihezi University, Shihezi 832003, PR China
1 shared publication
Latest Publications
- Open Access
- 18 March 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 198, 119260
In vitro activity and moderate in vivo efficacy of a novel β-carboline derivative against acute Toxoplasma gondii tachyzoites
- 18 March 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 198, 119260
Open AccessIn vitro activity and moderate in vivo efficacy of a novel β-carboline derivative against acute Toxoplasma gondii tachyzoites
- Open Access
Design, Synthesis, and Biological Evaluation of Novel N-Acylhydrazone Bond Linked Heterobivalent β-Carbolines as Potential Anticancer Agents
Utilizing a pharmacophore hybridization approach, we have designed and synthesized a novel series of 28 new heterobivalent β-carbolines. The in vitro cytotoxic potential of each compound was evaluated against the five cancer cell lines (LLC, BGC-823, CT-26, Bel-7402, and MCF-7) of different origin—murine and human, with the aim of determining the potency and selectivity of the compounds. Compound 8z showed antitumor activities with half-maximal inhibitory concentration (IC50) values of 9.9 ± 0.9, 8.6 ± 1.4, 6.2 ± 2.5, 9.9 ± 0.5, and 5.7 ± 1.2 µM against the tested five cancer cell lines. Moreover, the effect of compound 8z on the angiogenesis process was investigated using a chicken chorioallantoic membrane (CAM) in vivo model. At a concentration of 5 μM, compound 8z showed a positive effect on angiogenesis. The results of this study contribute to the further elucidation of the biological regulatory role of heterobivalent β-carbolines and provide helpful information on the development of vascular targeting antitumor drugs.
Open AccessDesign, Synthesis, and Biological Evaluation of Novel N-Acylhydrazone Bond Linked Heterobivalent β-Carbolines as Potential Anticancer Agents
Utilizing a pharmacophore hybridization approach, we have designed and synthesized a novel series of 28 new heterobivalent β-carbolines. The in vitro cytotoxic potential of each compound was evaluated against the five cancer cell lines (LLC, BGC-823, CT-26, Bel-7402, and MCF-7) of different origin—murine and human, with the aim of determining the potency and selectivity of the compounds. Compound 8z showed antitumor activities with half-maximal inhibitory concentration (IC50) values of 9.9 ± 0.9, 8.6 ± 1.4, 6.2 ± 2.5, 9.9 ± 0.5, and 5.7 ± 1.2 µM against the tested five cancer cell lines. Moreover, the effect of compound 8z on the angiogenesis process was investigated using a chicken chorioallantoic membrane (CAM) in vivo model. At a concentration of 5 μM, compound 8z showed a positive effect on angiogenesis. The results of this study contribute to the further elucidation of the biological regulatory role of heterobivalent β-carbolines and provide helpful information on the development of vascular targeting antitumor drugs.